Tyco/Mallinckrodt
This article was originally published in The Gray Sheet
Executive Summary
Firms receive second request for information from the Federal Trade Commission regarding Tyco's proposed acquisition of respiratory products maker Mallinckrodt for about $4.2 bil., announced June 28 (1"The Gray Sheet" July 3, 2000, p. 7). According to Tyco, the request relates specifically to the firms' respective sales of endotracheal tubes, and revenues from that product line amount to "less than $20 mil." The request raises the possibility that the FTC may require Tyco to divest the business before approving the overall deal. The firms still hope to close the deal by September
You may also be interested in...
Mallinckrodt Nellcor Puritan Bennett Line Breathes New Air Into Tyco
Tyco International's decision to account for its $4.2 bil. stock acquisition of Mallinckrodt as a purchase rather than a pooling-of-interests transaction, gives the company the flexibility to divest Mallinckrodt's imaging drugs and bulk pharmaceuticals businesses and concentrate on the fast-growing respiratory products division.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.